|
1
|
Johannesen TB, Langmark F and Lote K:
Cause of death and long-term survival in patients with
neuro-epithelial brain tumours: a population-based study. Eur J
Cancer. 39:2355–2363. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hess KR, Broglio KR and Bondy ML: Adult
glioma incidence trends in the United States, 1977–2000. Cancer.
101:2293–2299. 2004.PubMed/NCBI
|
|
3
|
Stummer W and Kamp MA: The importance of
surgical resection in malignant glioma. Curr Opin Neurol.
22:645–649. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Norden AD and Wen PY: Glioma therapy in
adults. Neurologist. 12:279–292. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Haan G and Gerrits A: Epigenetic
control of hematopoietic stem cell aging the case of Ezh2. Ann NY
Acad Sci. 1106:233–239. 2007.PubMed/NCBI
|
|
6
|
Venneti S, Le P, Martinez D, Xie SX,
Sullivan LM, Rorke-Adams LB, Pawel B and Judkins AR: Malignant
rhabdoid tumors express stem cell factors, which relate to the
expression of EZH2 and Id proteins. Am J Surg Pathol. 35:1463–1472.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Juan AH, Derfoul A, Feng X, Ryall JG,
Dell’Orso S, Pasut A, Zare H, Simone JM, Rudnicki MA and Sartorelli
V: Polycomb EZH2 controls self-renewal and safeguards the
transcriptional identity of skeletal muscle stem cells. Genes Dev.
25:789–794. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yonemitsu Y, Imazeki F, Chiba T, Fukai K,
Nagai Y, Miyagi S, Arai M, Aoki R, Miyazaki M, Nakatani Y, et al:
Distinct expression of polycomb group proteins EZH2 and BMI1 in
hepatocellular carcinoma. Hum Pathol. 40:1304–1311. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reijm EA, Jansen MP, Ruigrok-Ritstier K,
van Staveren IL, Look MP, van Gelder ME, Sieuwerts AM, Sleijfer S,
Foekens JA and Berns EM: Decreased expression of EZH2 is associated
with upregulation of ER and favorable outcome to tamoxifen in
advanced breast cancer. Breast Cancer Res Treat. 125:387–394. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hinz S, Weikert S, Magheli A, Hoffmann M,
Engers R, Miller K and Kempkensteffen C: Expression profile of the
polycomb group protein enhancer of Zeste homologue 2 and its
prognostic relevance in renal cell carcinoma. J Urol.
182:2920–2925. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Visser HP, Gunster MJ, Kluin-Nelemans HC,
Manders EM, Raaphorst FM, Meijer CJ, Willemze R and Otte AP: The
Polycomb group protein EZH2 is upregulated in proliferating,
cultured human mantle cell lymphoma. Br J Haematol. 112:950–958.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Smits M, Nilsson J, Mir SE, van der Stoop
PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J,
Krichevsky AM, et al: miR-101 is down-regulated in glioblastoma
resulting in EZH2-induced proliferation, migration, and
angiogenesis. Oncotarget. 1:710–720. 2010.PubMed/NCBI
|
|
14
|
Tomiyama A, Tachibana K, Suzuki K, Seino
S, Sunayama J, Matsuda KI, Sato A, Matsumoto Y, Nomiya T, Nemoto K,
et al: MEK-ERK-dependent multiple caspase activation by
mitochondrial proapoptotic Bcl-2 family proteins is essential for
heavy ion irradiation-induced glioma cell death. Cell Death Dis.
1:e602010. View Article : Google Scholar
|
|
15
|
Qiao S, Murakami K, Zhao Q, Wang B, Seo H,
Yamashita H, Li X, Iwamoto T, Ichihara M and Yoshino M:
Mimosine-induced apoptosis in C6 glioma cells requires the release
of mitochondria-derived reactive oxygen species and p38, JNK
activation. Neurochem Res. 37:417–427. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu HF, Chie YJ, Yang MS, Lee CS, Fu JJ,
Yang JS, Tan TW, Wu SH, Ma YS, Ip SW and Chung JG: Apigenin induces
caspase-dependent apoptosis in human lung cancer A549 cells through
Bax- and Bcl-2-triggered mitochondrial pathway. Int J Oncol.
36:1477–1484. 2010.PubMed/NCBI
|
|
17
|
Tang B, Zhang Y, Liang R, Yuan P, Du J,
Wang H and Wang L: Activation of the δ-opioid receptor inhibits
serum deprivation-induced apoptosis of human liver cells via the
activation of PKC and the mitochondrial pathway. Int J Mol Med.
28:1077–1085. 2011.
|
|
18
|
Dang X, Ma A, Yang L, Hu H, Zhu B, Shang
D, Chen T and Luo Y: MicroRNA-26a regulates tumorigenic properties
of EZH2 in human lung carcinoma cells. Cancer Genet. 205:113–123.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Esposito F, Tornincasa M, Pallante P,
Federico A, Borbone E, Pierantoni GM and Fusco A: Down-regulation
of the miR-25 and miR-30d contributes to the development of
anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J
Clin Endocrinol Metab. 97:E710–E718. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fussbroich B, Wagener N, Macher-Goeppinger
S, Benner A, Fälth M, Sültmann H, Holzer A, Hoppe-Seyler K and
Hoppe-Seyler F: EZH2 depletion blocks the proliferation of colon
cancer cells. PLoS One. 6:e216512011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li H, Cai Q, Godwin AK and Zhang R:
Enhancer of zeste homolog 2 promotes the proliferation and invasion
of epithelial ovarian cancer cells. Mol Cancer Res. 8:1610–1618.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ougolkov AV, Bilim VN and Billadeau DD:
Regulation of pancreatic tumor cell proliferation and
chemoresistance by the histone methyltransferase enhancer of zeste
homologue 2. Clin Cancer Res. 14:6790–6796. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wagener N, Holland D, Bulkescher J,
Crnković-Mertens I, Hoppe-Seyler K, Zentgraf H, Pritsch M, Buse S,
Pfitzenmaier J, Haferkamp A, et al: The enhancer of zeste homolog 2
gene contributes to cell proliferation and apoptosis resistance in
renal cell carcinoma cells. Int J Cancer. 123:1545–1550. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY
and Yu Q: Polycomb protein EZH2 regulates E2F1-dependent apoptosis
through epigenetically modulating Bim expression. Cell Death
Differ. 17:801–810. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu SC and Zhang Y: Cyclin-dependent kinase
1 (CDK1)-mediated phosphorylation of enhancer of zeste 2 (Ezh2)
regulates its stability. J Biol Chem. 286:28511–28519. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen S, Bohrer LR, Rai AN, Pan Y, Gan L,
Zhou X, Bagchi A, Simon JA and Huang H: Cyclin-dependent kinases
regulate epigenetic gene silencing through phosphorylation of EZH2.
Nat Cell Biol. 12:1108–1114. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
von Haefen C, Wendt J, Semini G, Sifringer
M, Belka C, Radetzki S, Reutter W, Daniel PT and Danker K:
Synthetic glycosidated phospholipids induce apoptosis through
activation of FADD, caspase-8 and the mitochondrial death pathway.
Apoptosis. 16:636–651. 2011.
|
|
28
|
Mattson MP and Kroemer G: Mitochondria in
cell death: novel targets for neuroprotection and cardioprotection.
Trends Mol Med. 9:196–205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saito M, Korsmeyer SJ and Schlesinger PH:
BAX-dependent transport of cytochrome c reconstituted in pure
liposomes. Nat Cell Biol. 2:553–555. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Riedl SJ and Shi Y: Molecular mechanisms
of caspase regulation during apoptosis. Nat Rev Mol Cell Biol.
5:897–907. 2004. View
Article : Google Scholar : PubMed/NCBI
|
